Kala Pharmaceuticals Inc. announced that the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a two-week course of therapy, has been accepted for review by the United States Food and Drug Administration FDA.

GW Pharmaceuticals plc announced that the U.S. FDA accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for Epidiolex (cannabidiol or CBD) as an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.